PsychiatricTimes Members: Login | Register

|     

PsychiatricTimes SearchMedica Medline Drugs

Powered by SearchMedica

 
Risk Assessment
News
Current Issues
Blogs
Special Reports
CME
Conferences
Resources
Careers
Multimedia
About Us
 

Home »

Psychiatric Times. Vol. 19 No. 10
Pages: 1  2  
Previous
 

Addiction Is a Disease

By John H. Halpern, M.D.
| October 1, 2002
Dr. Halpern is an instructor in psychiatry at Harvard Medical School and on staff at McLean Hospital and Brigham & Women's Hospital. He is the recipient of a Career Development Award (K23) from the National Institute on Drug Abuse for ongoing research at McLean Hospital's Alcohol and Drug Abuse Research Center.

Drug dependence changes the lives of users and those around them. Tobacco, for example, is the single greatest cause of preventable death in the United States (CDC, 2001). Certainly, then, tobacco is a menace to public health and its continued popularity supports nicotine(Drug information on nicotine) dependence as a chronic, relapsing disease in which volitional choice becomes but one negotiable variable in the struggle to achieve good health throughout the life cycle.

Moral rejectionists mislabel drug dependence as a failure of volition only and, thereby, claim a right to assign judgment and blame. The absurdity of looking through such a narrow lens is that if addiction really were merely a choice, people would stop after experiencing more harm than perceived benefits!

Accepting drug dependence as another mental illness does not typically abrogate responsibility for an addict's actions: Thousands each year are arrested, prosecuted and sentenced to serve jail time for simple drug possession, and, as for mental illness in general, consider that the two psychiatric inpatient facilities in the United States in which the largest numbers of patients reside are the Los Angeles County Jail and New York City Rikers Island Prison (Geller, 2000; Torrey, 1999; Watson et al., 2001). Obviously, such individuals' moment-to-moment decision-making can have long-term consequences that were never wished for or accurately anticipated.

Not all choices can be equally entertained at every given moment either, and sometimes other options are not even known. For example, a young woman, supporting herself and her drug habit through prostitution, may not know of the different "ethical" choices available to her, especially when as a child she had been introduced to both drugs and her career by her mother's example. The reasons for experimenting with addictive drugs, then, may be quite different from the motivations fueling continued use. Relapse is not due to an absolute loss of volitional control but rather to loss of a perspective that cherishes good health and mental well-being above other, less healthy choices. In high-risk situations, this long-term desire for maintaining better health through abstinence is overwhelmed by the cued wish to re-experience a known, anticipated "high" available at that moment.

Stigmatization of illness continues against many patients afflicted with brain pathology. Substance dependence is particularly stigmatized by those who wish to make this illness a debate over volition while denying the biological underpinnings of behavior. Moreover, demands for precise linguistic definitions of addiction and disease, as if they must forever be hermetically sealed within specific denotations of legalese and ethics, is of little value to physicians charged with the observation and treatment of pathology. History reveals many examples of debates over illness versus individual responsibility: Hansen's disease ("leprosy" from Mycobacterium leprae), seizure disorders ("epilepsy"), cancer and major depression are some examples of medical disorders now vindicated with the discovery of effective medications and procedures. Physicians, and psychiatrists in particular, are needed now more than ever to stand up and explain to the lay public how substance abuse and dependence can significantly alter brain function and physical health and that a variety of treatment modalities are available.

Effective management of drug dependence requires a medical model so as to tailor therapy according to the condition of the individual. Faith-based support groups, Alcohol(Drug information on alcohol)ics Anonymous and its affiliates, and long-term residential programs have a long history of assisting people in achieving and maintaining abstinence via a combination of direct therapy, education, cognitive skill-building exercises, expanded non-drug social supports and providing a drug-free environment. Contingency management skills can be taught to provide individuals with extra time to anticipate the high-risk situations and emotions for relapse and then, hopefully, re-script behavior to minimize such exposures (Carroll et al., 2001). This helps individuals learn to avoid night clubs or other users because such settings and people may make the choice for continued abstinence appear less valuable than the immediate reward anticipated with use.

Current pharmacotherapy for drug dependence includes screening for an underlying psychiatric condition after the patient has successfully completed detoxification. People may choose to self-medicate with an addictive drug, all the while unaware that they have a treatable psychiatric illness. For example, rates for alcoholism and other drug abuse are much higher in people with untreated bipolar disorder and depression. For motivated individuals, disulfiram(Drug information on disulfiram) (Antabuse) may particularly aid in maintaining sobriety from alcohol. Smoking tobacco while on the antidepressant buproprion (Zyban, Wellbutrin) is another aversive treatment, as the drug induces an undesirable taste when some smokers relapse. Agonist replacement medications assist with detoxification and/or offer a stable, safer maintenance therapy for those who repeatedly fail pure abstinence (e.g., methadone(Drug information on methadone) for opiate dependence, nicotine gum or patch for tobacco dependence). Many new medications are also in development including more opiate antagonists for the treatment of alcoholism and opiate dependence and NMDA antagonists such as acamprosate(Drug information on acamprosate) [Campral] for alcoholism (Tempesta et al., 2000). One day, perhaps there will even be a vaccine to confer natural immunity against cocaine (Schabacker et al., 2000). As Krystal et al. (2001) reported regarding the efficacy of naltrexone(Drug information on naltrexone) (ReVia), an opioid antagonist, in the treatment of alcoholism, sometimes medications do not prove to be as effective as promised. Evidence still suggests, however, that naltrexone may be quite effective if taken intermittently on the days that the individual feels at greater risk for relapse, rather than ingesting it every day (Boening et al., 2001).

Whether addiction is a disease or merely a choice, the utility of the medical model is needed to address resultant risks to public and individual health. A careful review of this growing body of scientific literature should offer hope that real solutions are possible. All other models for addressing drug dependence have, to date, proven to be costly failures, and doctors are not going to ignore viable treatment options for healing those suffering with drug dependence. Defining addiction as a choice only abdicates our responsibility for seeking health and true healing for our patients and, instead, leaves crushed lives dehumanized by a chronic relapsing condition with no hope for cure. As every doctor knows, "Remember to do some good" should quickly follow the first rule to "do no harm."

Pages: 1  2  
Previous
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





References
1.Boening JA, Lesch OM, Spanagel R et al. (2001), Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials. Alcohol Clin Exp Res 25(5 suppl ISBRA):127S-131S.
2.Bradberry CW (2000), Acute and chronic dopamine dynamics in a nonhuman primate model of recreational cocaine use. J Neurosci 20(18):7109-7115.
3.Cadoret RJ, Yates WR, Troughton E et al. (1995), Adoption study demonstrating two genetic pathways to drug abuse. Arch Gen Psychiatry 52(1):42-52.
3.Carroll KM, Ball SA, Nich C et al. (2001), Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 58(8):755-761.
4.CDC (2001), State-specific prevalence of current cigarette smoking among adults, and policies and attitudes about secondhand smoke‘United States, 2000. MMWR Morb Mortal Wkly Rep 50(49):1101-1106.
5.Childress AR, Mozley PD, McElgin W et al. (1999), Limbic activation during cue-induced cocaine craving. Am J Psychiatry 156(1):11-18.
6.Geller JL (2000), Excluding institutions for mental diseases from federal reimbursement for services: strategy or tragedy? Psychiatr Serv 51(11):1397-1403.
7.Goodman E, Capitman J (2000), Depressive symptoms and cigarette smoking among teens. Pediatrics 106(4):748-755.
8.Hyman SE (2001), A 28-year-old man addicted to cocaine. JAMA 286(20):2586-2594 [see comment].
9.Hyman SE, Malenka RC (2001), Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2(10):695-703.
10.Kelz MB, Nestler EJ (2000), deltaFosB: a molecular switch underlying long-term neural plasticity. Curr Opin Neurol 13(6):715-720.
11.Kendler KS, Karkowski LM, Neale MC, Prescott CA (2000), Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 57(3):261-269.
12.Krystal JH, Cramer JA, Krol WF et al. (2001), Naltrexone in the treatment of alcohol dependence. N Engl J Med 345(24):1734-1739 [see comment].
13.Matsumoto I, Wilce PA, Buckley T et al. (2001), Ethanol and gene expression in brain. Alcohol Clin Exp Res 25(5 suppl ISBRA):82S-86S.
14. Nestler EJ (2001), Molecular basis of long-term plasticity underlying addiction. [Published erratum Nat Rev Neurosci 2(3):215.] Nat Rev Neurosci 2(2):119-128.
15.Robinson TE, Kolb B (1999), Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur J Neurosci 11(5):1598-1604.
16.Rose JE (1996), Nicotine addiction and treatment. Annu Rev Med 47:493-507.
17. Schabacker DS, Kirschbaum KS, Segre M (2000), Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies. Immunology 100(1):48-56.
18.Spanagel R, Weiss F (1999), The dopamine hypothesis of reward: past and current status. Trends Neurosci 22(11):521-527.
19.Tempesta E, Janiri L, Bignamini A et al. (2000), Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcoholism 35(2):202-209.
20.Torrey EF (1999), Reinventing mental health care. City Journal 9(4):54-63.
21.Tsuang MT, Lyons MJ, Eisen SA et al. (1996), Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. Am J Med Genet 67(5):473-477.
22.Ungless MA, Whistler JL, Malenka RC, Bonci A (2001), Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 411(6837):583-587.
23.Walton R, Johnstone E, Munafo M et al. (2001), Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy. Trends Mol Med 7(2):70-76.
24.Watson A, Hanrahan P, Luchins D, Lurigio A (2001), Mental health courts and the complex issue of mentally ill offenders. Psychiatr Serv 52(4):477-481.
25.Wexler BE, Gottschalk CH, Fulbright RK et al. (2001), Functional magnetic resonance imaging of cocaine craving. Am J Psychiatry 158(1):86-95.


 
TOPIC INDEX

Addiction Medicine
Alzheimer Disease
Anxiety Disorders
ADHD
Bipolar Disorder
Child & Adolescent Psychiatry
Dementia
Depression
DSM-5
Geriatric Psychiatry

 

Health Care Reform
Major Depressive
Disorder
OCD
Personality Disorders
Schizoaffective Disorder
Schizophrenia
Sleep Disorders
Somatoform Disorders
All Topics

 


 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • The Moral Struggles of Practicing Psychiatrists
  • Developmental Psychopathology Comes of Age
  • Grief and Depression: The Sages Knew the Difference
  • Update on Mental Health Benefits and Substance Use Disorder Services Under the Affordable Care Act
  • Experts Discuss Changes, Updates in DSM-5
  • Grief and Depression: The Sages Knew the Difference
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Experts Discuss Changes, Updates in DSM-5
  • Synthetic Cathinones: Signs, Symptoms, and Treatment
  • Developmental Psychopathology Comes of Age
  • The Psychiatrist and the Slot Machine
  • The Role of Biological Tests in Psychiatric Diagnosis
  • You Are—And Your Mood Is—What You Eat
  • Experts Discuss Changes, Updates in DSM-5
  • The Paradox of Choice: When More Medications Mean Less Treatment
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • Grief and Depression: The Sages Knew the Difference
  • Psychiatry and the Myth of “Medicalization”
  • Is it Time for a Treatment Manual to Complement DSM-5?
  • NIMH vs DSM 5: No One Wins, Patients Lose
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
  • Experts Discuss Changes, Updates in DSM-5
  • The Role of Biological Tests in Psychiatric Diagnosis
  • Successful Aging: Strategies to Help Maintain and Nurture a Healthy Brain
  • Refinements in ECT Techniques
  • DSM-5 Won’t Solve the Overdiagnosis Problem—But Clinicians Can
Click here to subscribe to our newsletter
 
CAREER CENTER

  •   Featured Jobs  
  •    Resources   
  • Psychiatry and Nurse Practitioner Opportunities
  • Associate Medical Director - Psychiatrist Delray Beach, Florida
  • Retiring Child Psychiatrist Seeks Replacement August 2010 or Before
  • Chairperson, Dept of Psychiatry Needed
  • FT Staff Psychiatrist - Excellent Benefits
  • BC Adult and Child Psychiatrits - PT and FT Positions Available
  • Managing Risks When Practicing in Three-Party Care Settings
  • 12 Tips for Making Your Practice Greener
  • Keys to Avoiding Malpractice: Standard of Care in Psychiatric Practice
  • Take This Job and Shove It
  • Merging Administrative and Academic Careers in Psychiatry
 
SearchMedica SEARCH RESULT

Find peer-reviewed literature and websites for practicing medical professionals

CME on Display
Evidence on Display
Guidelines on Display
Patient Education on Display
Clinical Trials on Display
Practical Articles on Display
Research and Reviews on Display
All "Display" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy